Hyperfine (HYPR) Cash & Current Investments (2020 - 2026)
Hyperfine (HYPR) posted Cash & Current Investments of $41.3 million for Q1 2026, up 14.53% on a QoQ basis from $36.0 million in Q4 2025, and up 23.09% year-over-year from $33.5 million in Q1 2025.
Hyperfine (HYPR) Cash & Current Investments (2020 - 2026) Analysis & Trends
Hyperfine's Cash & Current Investments history runs 7 years deep, the most recent figure standing at $41.3 million for Q1 2026.
- Quarterly Cash & Current Investments rose 23.09% year-over-year to $41.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.3 million (up 23.09% YoY) and the FY2025 annual result came in at $36.0 million, down 4.33% from the prior year.
- Cash & Current Investments was $41.3 million for Q1 2026 at Hyperfine, up from $36.0 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $163.6 million in Q1 2022 and bottomed at $22.0 million in Q3 2025.
- A 5-year average of $75.5 million and a median of $63.2 million in 2024 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2022 — Cash & Current Investments jumped 104.26% — and 2025, when it sank 52.47%.
- Hyperfine's Cash & Current Investments stood at $118.2 million in 2022, then slumped by 35.89% to $75.8 million in 2023, then plunged by 50.3% to $37.7 million in 2024, then dropped by 4.33% to $36.0 million in 2025, then grew by 14.53% to $41.3 million in 2026.
- Business Quant data shows HYPR's Cash & Current Investments at $41.3 million in Q1 2026, $36.0 million in Q4 2025, and $22.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.64 Bn | 176.34 Bn | 6.27 Bn | 7.30 Bn |
| 2 | Stryker | 129.04 Bn | 126.16 Bn | 3.81 Bn | 2.88 Bn |
| 3 | Medtronic | 109.04 Bn | 99.82 Bn | 6.41 Bn | 9.22 Bn |
| 4 | Boston Scientific | 68.54 Bn | 67.08 Bn | 3.61 Bn | 1.45 Bn |
| 5 | Edwards Lifesciences | 48.67 Bn | 45.00 Bn | 1.29 Bn | 3.67 Bn |
| 6 | Dexcom | 28.40 Bn | 27.28 Bn | 750.30 Mn | 1.12 Bn |
| 7 | GE HealthCare Technologies | 28.37 Bn | 26.08 Bn | 1.98 Bn | 2.29 Bn |
| 8 | Smith & Nephew | 26.92 Bn | 26.34 Bn | - | 577.00 Mn |
| 9 | Koninklijke Philips | 25.48 Bn | 22.36 Bn | 2.07 Bn | 3.12 Bn |
| 10 | Hyperfine | 93.79 Mn | 52.51 Mn | 1.98 Mn | 41.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.28 Mn |
| Dec 31, 2025 | 36.04 Mn |
| Sep 30, 2025 | 22.03 Mn |
| Jun 30, 2025 | 25.58 Mn |
| Mar 31, 2025 | 33.53 Mn |
| Dec 31, 2024 | 37.67 Mn |
| Sep 30, 2024 | 45.98 Mn |
| Jun 30, 2024 | 53.81 Mn |
| Mar 31, 2024 | 63.20 Mn |
| Dec 31, 2023 | 75.80 Mn |
| Sep 30, 2023 | 85.97 Mn |
| Jun 30, 2023 | 94.92 Mn |
| Mar 31, 2023 | 104.74 Mn |
| Dec 31, 2022 | 118.24 Mn |
| Sep 30, 2022 | 133.74 Mn |
| Jun 30, 2022 | 146.71 Mn |
| Mar 31, 2022 | 163.56 Mn |
| Dec 31, 2021 | 191.16 Mn |
| Sep 30, 2021 | 65.48 Mn |
| Jun 30, 2021 | 77.39 Mn |